Private Capital Group’s Pacira BioSciences PCRX Stock Holding History

Private Capital Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2K	Hold	41	–	–	﹤0.01%	1570
2022 Q1	$3K	Buy	41 +9	+28%	+$600	﹤0.01%	1696
2021 Q4	$2K	Hold	32	–	–	﹤0.01%	1822
2021 Q3	$2K	Buy	32 +13	+68%	+$749	﹤0.01%	1878
2021 Q2	$1K	Sell	19 -4	-17%	-$253	﹤0.01%	2013
2021 Q1	$2K	Sell	23 -195	-89%	-$13.9K	﹤0.01%	1783
2020 Q4	$13K	Buy	218 +62	+40%	+$3.63K	﹤0.01%	1331
2020 Q3	$9K	Buy	+156	New	+$9.06K	﹤0.01%	1355

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Private Capital Group's PCRX Position: Q2 2022 in Review

Private Capital Group held its Pacira BioSciences (PCRX) position steady in Q2 2022 at 41 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

Private Capital Group first reported a position in PCRX in Q3 2020 and has held it in 8 quarters since. The position peaked at $13K in Q4 2020. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

Private Capital Group held 41 shares of Pacira BioSciences worth $2K as of Q2 2022.
Private Capital Group left its Pacira BioSciences share count unchanged in Q2 2022.
Pacira BioSciences made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1570 holding.
Private Capital Group first reported a position in Pacira BioSciences in Q3 2020 and has held it in 8 quarters since.
Private Capital Group's Pacira BioSciences position peaked at $13K in Q4 2020.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.